---
title: Improve motor and cognitive function
nct_id: NCT07271927
phase: NA
status: RECRUITING
sponsor: Pusan National University Yangsan Hospital
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07271927"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07271927"
last_fetched: "2026-05-10T14:06:21.316Z"
source: "Parkinson's Pathways (curated)"
---
# Improve motor and cognitive function

**Goal (in five words):** Improve motor and cognitive function

**Official Title:** Evaluation Study of the Effects and Safety of Whole-Body Photobiomodulation Therapy on Motor and Cognitive Changes in Patients With Parkinson's Disease

**Trial ID:** [NCT07271927](https://clinicaltrials.gov/study/NCT07271927)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Pusan National University Yangsan Hospital
- **Target Enrollment:** 15 participants
- **Start Date:** 2025-02-12
- **Completion Date:** 2025-11-30
- **Conditions:** PARKINSON DISEASE (Disorder)
- **Interventions:** Photobiomodulation
- **Intervention Types:** DEVICE

## Summary For Families

The trial wants to find out whether whole-body photobiomodulation can improve movement and thinking problems in people with Parkinson's, while checking that the treatment is safe. Photobiomodulation uses low-level red and near-infrared light applied to the body to stimulate mitochondria, boost cellular energy (ATP), and reduce inflammation and oxidative stress, which may protect neurons and help motor and cognitive function; it is a non-drug therapy meant to be used alongside standard medications like levodopa, not to replace them. Adults aged 40 and up with Parkinson's at Hoehn and Yahr stages 1 to 3 who can walk independently are eligible, while people with very severe cognitive impairment (K-MMSE ≤ 9), implanted electronic devices, a history of seizures or serious psychiatric or medical issues, pregnancy, or recent participation in multiple trials are excluded.

## Eligibility

- **Minimum age:** 40 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Individuals diagnosed with Parkinson's disease at Hoehn and Yahr stages 1-3 based on medical history and examination
* Adults aged 40 years or older
* Individuals able to walk independently

Exclusion Criteria:

* Individuals with severe cognitive impairment (Korean Mini-Mental State Examination \[K-MMSE\] score ≤ 9) making it difficult to understand and perform tasks
* Patients with dementia other than Parkinson's disease dementia
* Individuals with implanted medical or other electronic devices
* Individuals with severe neuropsychiatric disorders
* Individuals treated for alcohol dependence within 6 months prior to screening
* Individuals with a history of suicide attempts
* Individuals with a history of seizures
* Individuals experiencing dyspnea while sitting at rest
* Individuals with visual impairment preventing them from reading ordinary text even with corrective lenses
* Individuals with hearing impairment preventing them from understanding conversation even with a hearing aid
* Individuals who have participated in two or more clinical trials in the same year or in another clinical trial within the past 6 months
* Women and men of childbearing potential who are planning pregnancy during the trial or who do not agree to use appropriate contraceptive methods
* Pregnant or breastfeeding women
* Individuals deemed medically inappropriate for participation by the principal investigator or study staff based on clinically significant findings not otherwise specified above
```

## Locations (1)

- Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnam-do, South Korea _(35.3420, 129.0336)_
  - Youjin Jeong — (CONTACT) — +82-55-360-4720 — gamza33@naver.com

## Central Contacts

- Jisoo Baik — (CONTACT) — 082+055-360-4159 — zisoo@pusan.ac.kr

---

*Canonical: https://parkinsonspathways.com/trial/NCT07271927*  
*HTML version: https://parkinsonspathways.com/trial/NCT07271927*  
*Source data: https://clinicaltrials.gov/study/NCT07271927*